drugset
drugset / Trial / NCT06445907

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

NCT06445907 ↗

Phase 1 Active not recruiting 17 enrolled M.D. Anderson Cancer Center Qurient Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.

Timeline

Start
2025-02-12
Primary completion
2027-07-01
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Intravenous
Subject Q702 Small molecule — Oral
Subject Venetoclax Small molecule — Oral

Indications

acute myeloid leukemia